0001572426-17-000022.txt : 20170802
0001572426-17-000022.hdr.sgml : 20170802
20170802212539
ACCESSION NUMBER: 0001572426-17-000022
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gunn George W
CENTRAL INDEX KEY: 0001639458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 171001900
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NIBRT, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 0000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-07-31
1
0001618561
Nexvet Biopharma plc
NVET
0001639458
Gunn George W
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE
L2
R35 FR98
IRELAND
1
0
0
0
Ordinary Shares
2017-07-31
4
D
0
42600
6.72
D
0
D
Restricted Share Units
.125
2017-07-31
4
D
0
1500
6.595
D
2019-07-01
Ordinary Shares
1500
0
D
Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
This restricted share unit, which would have vested and become convertible as to 500 shares on each of 9/30/17, 12/31/17 and 3/31/18, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $9,892.50. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
/s/ George W. Gunn by Geraldine T. Farrell, Attorney-in-Fact
2017-07-31